{
"id":"mk19_a_id_s16",
"subspecialtyId":"id",
"title":"Infections in Transplant Recipients",
"jsonContent":{
"type":"section",
"id":"mk19_a_id_s16",
"title":{
"__html":"Infections in Transplant Recipients"
},
"titleNode":{
"type":"section-title",
"hlId":"0d9361",
"children":[
"Infections in Transplant Recipients"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s16_1",
"title":{
"__html":"Introduction"
},
"titleNode":{
"type":"section-title",
"hlId":"0b7979",
"children":[
"Introduction"
]
},
"children":[
{
"type":"p",
"hlId":"aa5b44",
"children":[
"The occurrence of solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) procedures continues to increase, as do long-term survival rates owing to improved management of rejection and decreased complications. With more patients living longer after transplantation, awareness of principles involved in the recognition and prevention of infection in transplant recipients remains important for physicians who are not transplant specialists."
]
},
{
"type":"p",
"hlId":"5529bd",
"children":[
"Despite improvements in immunosuppression and antimicrobial therapy, infection remains a significant cause of morbidity and mortality after SOT and HSCT. Infection is the most common cause of death in the first year after SOT. Additionally, the interaction of the immune system and infection is bidirectional; although immune suppression to prevent rejection increases risk of infection, infection also raises the risk of rejection."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s16_2",
"title":{
"__html":"Antirejection Drugs in Transplant Recipients"
},
"titleNode":{
"type":"section-title",
"hlId":"58351c",
"children":[
"Antirejection Drugs in Transplant Recipients"
]
},
"children":[
{
"type":"p",
"hlId":"2c6b0d",
"children":[
"Success after transplantation depends on modulating the immune system to prevent organ rejection in SOT and to minimize graft-versus-host disease (GVHD) in allogeneic HSCT. Antirejection regimens involve multiple agents ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t50",
"wrapId":"1",
"children":[
"Table 50"
]
}
]
},
")"
]
},
" with different mechanisms of action, which are chosen to minimize overlapping toxicities. After SOT, an induction and maintenance strategy is applied; immunosuppression is most intensive in the first month after transplantation and often includes lymphocyte depletion therapy. Immunosuppression may require intensification during episodes of rejection, with associated increased risk of infection."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_id_t50"
]
},
{
"type":"p",
"hlId":"85197c",
"children":[
"Steroid-sparing or minimizing regimens are increasingly used to avoid the toxicities of long-term steroid therapy. Tacrolimus, cyclosporine, or sirolimus are the cornerstones, usually with mycophenolate or, less commonly, azathioprine. Drug interactions are common with these agents, and many drugs can affect antirejection medication levels. Monitoring is important to balance adequate immunosuppression with toxicity."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"918fad",
"children":[
"Glucocorticoid-sparing or minimizing regimens (with tacrolimus, cyclosporine, or sirolimus) are increasingly used to avoid the toxicities of long-term steroid therapy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s16_3",
"title":{
"__html":"Posttransplantation Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"6ca220",
"children":[
"Posttransplantation Infections"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s16_3_1",
"title":{
"__html":"Timeline and Type of Transplant"
},
"titleNode":{
"type":"section-title",
"hlId":"e13db5",
"children":[
"Timeline and Type of Transplant"
]
},
"children":[
{
"type":"p",
"hlId":"200a35",
"children":[
"Infection may occur at any time after transplantation, but periods of highest immunosuppression, usually within the first few months after transplantation, carry the highest likelihood. Risk for infection is also affected by pre-existing conditions (such as diabetes mellitus, cirrhosis, or neutropenia) and by colonization with resistant organisms (such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Burkholderia"
]
},
" in cystic fibrosis)."
]
},
{
"type":"p",
"hlId":"277bae",
"children":[
"The specific infection risk varies depending on the time after transplantation. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_a_id_v01",
"wrapId":"2",
"children":[
"Video 1"
]
}
]
},
" shows common infections in the early and later periods, and ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t51",
"wrapId":"2",
"children":[
"Table 51"
]
}
]
},
" lists the typical timeline of risk for specific infections after SOT. However, the timeline restarts when treating episodes of rejection, and infection risk in the late period depends on the immunosuppression level required. In the first month after SOT, infections are similar to those seen in other hospitalized postsurgical patients, including a risk of resistant bacteria, and most often involve the lungs, urinary tract, and surgical sites",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"."
]
},
" The middle period usually encompasses the most intensive immunosuppression, with significant risk for viral (such as cytomegalovirus) and fungal (such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis"
]
},
") infections owing to defects in cell-mediated immunity. If immunosuppression can be de-escalated during the late period, risk for opportunistic infections decreases overall, but patients remain at risk for certain viral infections and have increased risk for community-acquired bacterial infections."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_a_id_v01",
"mk19_a_id_t51"
]
},
{
"type":"p",
"hlId":"0d02ba",
"children":[
"For some infections, the risk strongly depends on donor and recipient characteristics. Standard donor and recipient pretransplantation testing includes serologies for cytomegalovirus; Epstein-Barr virus; varicella-zoster virus; HIV; hepatitis B, C, and E viruses; syphilis; toxoplasmosis; and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Strongyloides"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Leishmania"
]
},
", and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Trypanosoma"
]
},
" if from an endemic area; and interferon-γ release assay for latent tuberculosis infection. Immunosuppressive drugs and changed anatomy after transplantation may also contribute to altered presentations, making diagnosis of common infections more challenging. Noninfectious complications such as GVHD or malignancy may also be confused with infection."
]
},
{
"type":"p",
"hlId":"0adc3b",
"children":[
"Risk after HSCT is much greater for allogeneic than autologous transplantation because of the myeloablative conditioning regimen. After allogeneic HSCT, patients undergo a prolonged period of intense neutropenia, putting them at risk for bacterial infections, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" and mold infections, and herpes simplex and other virus reactivation. This is followed by a prolonged period of impaired cell-mediated and humoral immunity because of immunosuppression to reduce GVHD. Development of chronic GVHD can also increase risk for infections caused by immune system effects and breakdowns in mucosal and other barriers. Infections in this later period are similar to those in the later period after SOT. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f33",
"wrapId":"3",
"children":[
"Figure 33"
]
}
]
},
" shows the timeline of risk for specific infections after allogeneic HSCT."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_a_id_f33"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"da77c0",
"children":[
"Infection may occur at any time after transplantation but is most likely at periods of highest immunosuppression; the risk for specific organisms varies depending on the time after transplantation."
]
},
{
"type":"keypoint",
"hlId":"7d50ca",
"children":[
"Infection risk is much greater after allogeneic than autologous hematopoietic stem cell transplantation because of myeloablative conditioning with a prolonged period of neutropenia and immunosuppression given to reduce graft-versus-host disease."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s16_3_2",
"title":{
"__html":"Specific Posttransplantation Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"eba6f7",
"children":[
"Specific Posttransplantation Infections"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s16_3_2_1",
"title":{
"__html":"Viral Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"7cc885",
"children":[
"Viral Infections"
]
},
"children":[
{
"type":"p",
"hlId":"e1b44d",
"children":[
"Cytomegalovirus is the most significant viral infection after transplantation, with risk for infection depending on donor and recipient serology (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_a_id_v02",
"wrapId":"4",
"children":[
"Video 2"
]
}
]
},
"). After SOT, the risk for cytomegalovirus is highest (>50%) for donor-positive/recipient-negative, intermediate (15%-20%) for recipient-positive, and lowest for donor-negative/recipient-negative transplantations. Risk is also significantly increased with use of lymphocyte-depleting agents. Comparatively, after allogeneic HSCT, the risk of cytomegalovirus is highest for donor-negative/recipient-positive transplantations. Cytomegalovirus is an immunomodulatory virus, and active cytomegalovirus infection after transplantation is associated with increased rates of rejection and GVHD, as well as increases in other opportunistic infections and posttransplant lymphoproliferative disorder (PTLD). Cytomegalovirus often presents as a nonspecific viral syndrome with fever and cytopenias. Specific organ disease owing to cytomegalovirus includes pneumonitis (more common in HSCT than SOT), encephalitis, hepatitis, and other gastrointestinal sites. Colitis is the most common manifestation of cytomegalovirus gastrointestinal disease after SOT, whereas esophagitis is more common after HSCT. Definitive diagnosis of organ disease depends on demonstration of cytomegalovirus in biopsy, although presumptive diagnosis can be made based on cytomegalovirus viremia, using quantitative nucleic acid amplification testing, in the appropriate clinical setting."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_a_id_v02"
]
},
{
"type":"p",
"hlId":"fd5b46",
"children":[
"Epstein-Barr virus is most significant for its relationship to PTLD resulting from B-cell proliferation; PTLD should be suspected in any patient in the middle or late period presenting with lymphadenopathy or an extranodal mass, often with fever. Treatment of PTLD involves rituximab and decreasing immunosuppression. Reactivation of herpes simplex virus is especially common after HSCT and can be reduced with acyclovir prophylaxis (if the patient is not already receiving an agent for cytomegalovirus). Patients with chronic hepatitis B can have disease flares if not taking suppressive therapy (see ",
{
"type":"cross-reference",
"target":"mk19_a_gi_s6_2_2",
"children":[
"MKSAP 19 Gastroenterology & Hepatology"
]
},
"). Polyomavirus BK can cause nephropathy after kidney transplantation, increasing the risk of graft rejection, and hemorrhagic cystitis, particularly in HSCT."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s16_3_2_2",
"title":{
"__html":"Bacterial Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"9cbb10",
"children":[
"Bacterial Infections"
]
},
"children":[
{
"type":"p",
"hlId":"b8be14",
"children":[
"Bacterial infections are common in the early period after SOT and during neutropenia after HSCT. These are often typical nosocomial infections, including resistant organisms such as methicillin-resistant staphylococci, vancomycin-resistant enterococci, and multidrug-resistant gram-negative organisms. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Clostridioides difficile"
]
},
" colitis is common, especially with the extensive antibiotic use that accompanies transplantation. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
},
" can reactivate with the immunosuppression of transplantation and may present with an atypical pattern on chest radiography or with extrapulmonary disease. Related to persistently low antibody levels, encapsulated organisms such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Streptococcus pneumoniae"
]
},
" remain common even late after HSCT."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s16_3_2_3",
"title":{
"__html":"Fungal Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"acf849",
"children":[
"Fungal Infections"
]
},
"children":[
{
"type":"p",
"hlId":"f18ada",
"children":[
"Fungal infections are most common in the middle period after SOT but may also occur late, especially in the setting of increased immunosuppression for the treatment of rejection or profound T-cell depression secondary to cytomegalovirus infection. Without prophylaxis, the most common fungal infection is ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis"
]
},
" pneumonia, which presents as a more acute and severe pneumonitis in patients after transplantation than in those with AIDS. Cryptococcosis usually presents as subacute meningitis with fever, headache, mental status changes, and lymphocytic pleocytosis in cerebrospinal fluid, although skin and other organ involvement may also occur; cryptococcal antigen testing is key to diagnosis. Histoplasmosis may also occur in geographically endemic areas and is more likely to present with disseminated disease after transplantation. Mucocutaneous candidiasis is common early after SOT and HSCT. Invasive ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" infections and candidemia can be seen, especially in the neutropenic phase after HSCT, as can aspergillosis and other invasive molds, such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mucor"
]
},
". The risk for invasive fungal infections after HSCT is also increased in later periods by the use of immunosuppressive agents for GVHD. In SOT, pulmonary aspergillosis is most common after lung transplantation."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s16_3_2_4",
"title":{
"__html":"Protozoa and Helminths"
},
"titleNode":{
"type":"section-title",
"hlId":"075415",
"children":[
"Protozoa and Helminths"
]
},
"children":[
{
"type":"p",
"hlId":"389085",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Toxoplasma gondii"
]
},
", a risk particularly for heart transplant recipients, is a protozoan that can reactivate with immunosuppression, causing encephalitis with fever, headache, and focal neurologic deficits with multiple ring-enhancing brain lesions on imaging (see ",
{
"type":"cross-reference",
"target":"mk19_a_id_s18_5_5",
"children":[
"HIV/AIDS"
]
},
"). ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Strongyloides"
]
},
" can cause a hyperinfection syndrome with significant immunosuppression (especially glucocorticoid use), often with secondary pneumonia and gram-negative bacteremia. Reactivation of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Trypanosoma"
]
},
" or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Leishmania"
]
},
" can also occur after transplantation, if the recipient or donor was from an endemic area."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"7dcc28",
"children":[
"Cytomegalovirus is the most significant viral infection after transplantation and may present as a nonspecific viral syndrome with fever and cytopenias or with specific organ disease, including pneumonitis, encephalitis, esophagitis, and colitis."
]
},
{
"type":"keypoint",
"hlId":"7d7285",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Clostridioides difficile"
]
},
" colitis is common after transplantation, complicating the extensive antibiotic use that accompanies transplantation."
]
},
{
"type":"keypoint",
"hlId":"b53a98",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
},
" can reactivate with the immunosuppression of transplantation and may present with an atypical pattern on chest radiography or with extrapulmonary disease."
]
},
{
"type":"keypoint",
"hlId":"9eb31f",
"children":[
"Without prophylaxis, the most common fungal infection is ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis"
]
},
" pneumonia, which presents as a more acute and severe pneumonitis in patients after transplantation than in those with AIDS."
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s16_4",
"title":{
"__html":"Prevention of Infections in Transplant Recipients"
},
"titleNode":{
"type":"section-title",
"hlId":"63b15a",
"children":[
"Prevention of Infections in Transplant Recipients"
]
},
"children":[
{
"type":"p",
"hlId":"815d01",
"children":[
"Prevention is preferred over treatment strategies for most common infections after transplantation because most opportunistic infections have devastating effects and the cost and toxicity of prophylaxis and immunization are relatively low. Recommended immunizations for SOT and HSCT are shown in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t52",
"wrapId":"5",
"children":[
"Table 52"
]
}
]
},
". Most immunizations are safe in patients after transplantation except for live virus vaccines, which should be avoided after transplantation."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_a_id_t52"
]
},
{
"type":"p",
"hlId":"361012",
"children":[
"Trimethoprim-sulfamethoxazole is one of the most important prophylactic medications after transplantation. Used to prevent ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis"
]
},
", it may also reduce toxoplasmosis and certain bacteria, including ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Listeria"
]
},
" and agents causing urinary tract infections."
]
},
{
"type":"p",
"hlId":"d7a6dc",
"children":[
"Antifungal prophylaxis is indicated during the early months after HSCT and may need to be extended in the setting of GVHD. Coverage should include ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Aspergillus"
]
},
", typically with posaconazole or voriconazole."
]
},
{
"type":"p",
"hlId":"5de598",
"children":[
"Strategies to reduce the effects of cytomegalovirus include primary prophylaxis, usually with valganciclovir, or regular monitoring for active cytomegalovirus replication by quantitative nucleic acid amplification testing and institution of pre-emptive therapy based on results. Monitoring and pre-emptive therapy is more often used after HSCT, partially because of increased concerns for neutropenia as an adverse effect of prophylaxis and because prophylaxis was not found to be superior to pre-emptive therapy in a randomized controlled trial. Letermovir, a novel antiviral agent without the hematologic toxicities of valganciclovir, is approved for prophylaxis of cytomegalovirus infection in bone marrow transplant recipients. For SOT, prophylaxis with valganciclovir is preferred for patients at high risk (donor-positive/recipient-negative, those receiving lymphocyte-depleting agents, lung transplants) and is usually given for at least 3 to 6 months; letermovir prophylaxis is under study in SOT recipients."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"3ae993",
"hvc":true,
"children":[
"Prophylaxis and immunization are preferred over treating active infections after transplantation; live virus vaccines should be avoided after transplantation."
]
},
{
"type":"keypoint",
"hlId":"819894",
"children":[
"Monitoring by quantitative nucleic acid amplification testing for active cytomegalovirus replication and institution of pre-emptive therapy based on results is preferred to ganciclovir primary prophylaxis of cytomegalovirus infection after hematopoietic stem cell transplantation."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s16_5",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014;342:1-8. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24041869",
"target":"_blank"
},
"children":[
"PMID: 24041869"
]
},
" doi:10.1016/j.canlet.2013.09.004"
]
},
{
"type":"reference",
"children":[
"Fishman JA. From the classic concepts to modern practice. Clin Microbiol Infect. 2014;20 Suppl 7:4-9. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24528498",
"target":"_blank"
},
"children":[
"PMID: 24528498"
]
},
" doi:10.1111/1469-0691.12593"
]
},
{
"type":"reference",
"children":[
"Fleming S, Yannakou CK, Haeusler GM, Clark J, Grigg A, Heath CH, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44:1283-97. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25482741",
"target":"_blank"
},
"children":[
"PMID: 25482741"
]
},
" doi:10.1111/imj.12595"
]
},
{
"type":"reference",
"children":[
"Lumbreras C, Manuel O, Len O, ten Berge IJ, Sgarabotto D, Hirsch HH. Cytomegalovirus infection in solid organ transplant recipients. Clin Microbiol Infect. 2014;20 Suppl 7:19-26. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26451404",
"target":"_blank"
},
"children":[
"PMID: 26451404"
]
}
]
},
{
"type":"reference",
"children":[
"Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309-18. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24421306",
"target":"_blank"
},
"children":[
"PMID: 24421306"
]
},
" doi:10.1093/cid/cit816"
]
},
{
"type":"reference",
"children":[
"Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W, et al; Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation). Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016;95:1435-55. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27339055",
"target":"_blank"
},
"children":[
"PMID: 27339055"
]
},
" doi:10.1007/s00277-016-2711-1"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_a_id_t50":{
"id":"mk19_a_id_t50",
"number":50,
"bookId":"id",
"title":{
"__html":"Immunosuppressive Agents Used in Transplantation"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"6c068f",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 50. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t50"
}
]
},
"Immunosuppressive Agents Used in Transplantation"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bd813",
"class":"col hd l",
"children":[
"Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"375099",
"class":"col hd l",
"children":[
"Agents"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"adb71f",
"class":"cell txt l",
"children":[
"Glucocorticoids"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b4a8bd",
"class":"cell txt l",
"children":[
"Prednisone, others"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"223a47",
"class":"cell txt l",
"children":[
"Cytotoxic agents (DNA synthesis inhibitors, antimetabolites)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31de20",
"class":"cell txt l",
"children":[
"Mycophenolate mofetil"
]
},
" ",
{
"type":"p",
"hlId":"a52af3",
"class":"cell txt l",
"children":[
"Mycophenolate sodium"
]
},
" ",
{
"type":"p",
"hlId":"ac0373",
"class":"cell txt l",
"children":[
"Azathioprine"
]
},
" ",
{
"type":"p",
"hlId":"b98cff",
"class":"cell txt l",
"children":[
"Methotrexate"
]
},
" ",
{
"type":"p",
"hlId":"3ce44b",
"class":"cell txt l",
"children":[
"Cyclophosphamide"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea9908",
"class":"cell txt l",
"children":[
"Calcineurin pathway inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d5ad08",
"class":"cell txt l",
"children":[
"Cyclosporine"
]
},
" ",
{
"type":"p",
"hlId":"273268",
"class":"cell txt l",
"children":[
"Tacrolimus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec803a",
"class":"cell txt l",
"children":[
"mTOR inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"46ed49",
"class":"cell txt l",
"children":[
"Sirolimus (rapamycin)"
]
},
" ",
{
"type":"p",
"hlId":"0a76ba",
"class":"cell txt l",
"children":[
"Everolimus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5145b6",
"class":"cell txt l",
"children":[
"Lymphocyte-depleting antibodies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39ef3c",
"class":"cell txt li",
"children":[
"Polyclonal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e8a9ff",
"class":"cell txt l",
"children":[
"Antithymocyte globulins"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8e746",
"class":"cell txt li",
"children":[
"Monoclonal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9aafc7",
"class":"cell txt l",
"children":[
"Muromonab (anti-CD3)"
]
},
" ",
{
"type":"p",
"hlId":"f978a7",
"class":"cell txt l",
"children":[
"Basiliximab (anti–IL-2 receptor)"
]
},
" ",
{
"type":"p",
"hlId":"9608b6",
"class":"cell txt l",
"children":[
"Daclizumab (anti–IL-2 receptor)"
]
},
" ",
{
"type":"p",
"hlId":"36c88a",
"class":"cell txt l",
"children":[
"Rituximab (anti-CD20)"
]
},
" ",
{
"type":"p",
"hlId":"a6aec0",
"class":"cell txt l",
"children":[
"Alemtuzumab (anti-CD52)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IL-2 = interleukin-2; mTOR = mammalian target of rapamycin."
]
]
},
"mk19_a_id_t51":{
"id":"mk19_a_id_t51",
"number":51,
"bookId":"id",
"title":{
"__html":"Timeline of Common Infections after Solid Organ Transplantation"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"22f257",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 51. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t51"
}
]
},
"Timeline of Common Infections after Solid Organ Transplantation"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da4217",
"class":"col hd l",
"children":[
"Early Period (<1 Month after Transplantation)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"74e694",
"class":"col hd l",
"children":[
"Middle Period (1-6 Months after Transplantation)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"68588c",
"class":"col hd l",
"children":[
"Late Period (>6 Months after Transplantation)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"883a42",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" infection (including methicillin-resistant)"
]
},
" ",
{
"type":"p",
"hlId":"27769e",
"class":"cell txt l",
"children":[
"Nosocomial gram-negative bacterial infection"
]
},
" ",
{
"type":"p",
"hlId":"b4dc4d",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Clostridioides difficile"
]
},
" colitis"
]
},
" ",
{
"type":"p",
"hlId":"9c8609",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" infection"
]
},
" ",
{
"type":"p",
"hlId":"0b041d",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Aspergillus"
]
},
" infection"
]
},
" ",
{
"type":"p",
"hlId":"e41981",
"class":"cell txt l",
"children":[
"Surgical site infections"
]
},
" ",
{
"type":"p",
"hlId":"55a073",
"class":"cell txt l",
"children":[
"Hospital-acquired pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"e71b7f",
"class":"cell txt l",
"children":[
"Catheter-related bacteremia"
]
},
" ",
{
"type":"p",
"hlId":"b06664",
"class":"cell txt l",
"children":[
"Urinary tract infections"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9535e",
"class":"cell txt l",
"children":[
"Cytomegalovirus infection"
]
},
" ",
{
"type":"p",
"hlId":"412020",
"class":"cell txt l",
"children":[
"Epstein-Barr virus (including PTLD) infection"
]
},
" ",
{
"type":"p",
"hlId":"7ed672",
"class":"cell txt l",
"children":[
"Herpes simplex virus infection"
]
},
" ",
{
"type":"p",
"hlId":"7a4a49",
"class":"cell txt l",
"children":[
"Varicella-zoster virus infection"
]
},
" ",
{
"type":"p",
"hlId":"2bfa5a",
"class":"cell txt l",
"children":[
"Polyomavirus BK infection"
]
},
" ",
{
"type":"p",
"hlId":"489295",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis jirovecii"
]
},
" infection"
]
},
" ",
{
"type":"p",
"hlId":"60354d",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Toxoplasma, Trypanosoma, Strongyloides"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"3bb202",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Listeria"
]
},
" infection"
]
},
" ",
{
"type":"p",
"hlId":"2be9e3",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Nocardia"
]
},
" infection"
]
},
" ",
{
"type":"p",
"hlId":"993727",
"class":"cell txt l",
"children":[
"Tuberculosis reactivation"
]
},
" ",
{
"type":"p",
"hlId":"6699d2",
"class":"cell txt l",
"children":[
"Fungal infections, including ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Cryptococcus"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"412020",
"class":"cell txt l",
"children":[
"Epstein-Barr virus (including PTLD) infection"
]
},
" ",
{
"type":"p",
"hlId":"7a4a49",
"class":"cell txt l",
"children":[
"Varicella-zoster virus infection"
]
},
" ",
{
"type":"p",
"hlId":"089e27",
"class":"cell txt l",
"children":[
"Community-acquired pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"b06664",
"class":"cell txt l",
"children":[
"Urinary tract infections"
]
},
" ",
{
"type":"p",
"hlId":"2bfa5a",
"class":"cell txt l",
"children":[
"Polyomavirus BK infection"
]
},
" ",
{
"type":"p",
"hlId":"d9535e",
"class":"cell txt l",
"children":[
"Cytomegalovirus infection"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"PTLD = posttransplant lymphoproliferative disorder."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"For opportunistic infections in the late period, risk depends on level of immunosuppression. Infections such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis"
]
},
" and other fungi, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Listeria"
]
},
", and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Nocardia"
]
},
" can be seen in the late period in patients with higher immunosuppression."
]
]
},
"mk19_a_id_t52":{
"id":"mk19_a_id_t52",
"number":52,
"bookId":"id",
"title":{
"__html":"Immunization Recommendations for Adult Recipients of Transplants<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"485053",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 52. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t52"
}
]
},
"Immunization Recommendations for Adult Recipients of Transplants",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3bca2",
"class":"col hd l",
"children":[
"Immunization"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a9f714",
"class":"col hd l",
"children":[
"Recommendations for Solid Organ Transplantation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c4788",
"class":"col hd l",
"children":[
"Recommendations for Hematopoietic Stem Cell Transplantation",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a0ccce",
"class":"cell txt l",
"children":[
"Pneumococcal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"474890",
"class":"cell txt l",
"children":[
"Previous recommendations included PCV13 followed by PPSV23. Revised recommendations for administration of PCV15, PCV20, and PPSV23 in transplant patients have yet to be provided."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"474890",
"class":"cell txt l",
"children":[
"Previous recommendations included PCV13 followed by PPSV23. Revised recommendations for administration of PCV15, PCV20, and PPSV23 in transplant patients have yet to be provided."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5947dd",
"class":"cell txt l",
"children":[
"Influenza (inactivated only)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10b342",
"class":"cell txt l",
"children":[
"Annually"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10b342",
"class":"cell txt l",
"children":[
"Annually"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c24177",
"class":"cell txt l",
"children":[
"Tdap"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4e3ad9",
"class":"cell txt l",
"children":[
"Before transplantation: complete series, including Tdap booster"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a60d1",
"class":"cell txt l",
"children":[
"6 months after transplantation: three doses Tdap"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da2733",
"class":"cell txt l",
"children":[
"MMR"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8e707",
"class":"cell txt l",
"children":[
"Contraindicated after transplantation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c29c48",
"class":"cell txt l",
"children":[
"24 months after transplantation: two doses, only if no GVHD or immune suppression"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e3b25",
"class":"cell txt l",
"children":[
"Inactivated polio"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de5765",
"class":"cell txt l",
"children":[
"Before transplantation: complete series"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47e0d6",
"class":"cell txt l",
"children":[
"6-12 months after transplantation: three doses"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"84e2b0",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Haemophilus influenzae"
]
},
" type B"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d85159",
"class":"cell txt l",
"children":[
"No recommendation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47e0d6",
"class":"cell txt l",
"children":[
"6-12 months after transplantation: three doses"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df6499",
"class":"cell txt l",
"children":[
"Meningococcal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e3e13",
"class":"cell txt l",
"children":[
"Per recommendations for nontransplant patients"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e5d762",
"class":"cell txt l",
"children":[
"6-12 months after transplantation per recommendations for nontransplant patients"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6836fb",
"class":"cell txt l",
"children":[
"Hepatitis B"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"496dd1",
"class":"cell txt l",
"children":[
"Before transplantation: complete series if not already immune"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d5147e",
"class":"cell txt l",
"children":[
"6-12 months after transplantation: three doses if indications for nontransplant patients are met"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"038690",
"class":"cell txt l",
"children":[
"Hepatitis A"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"496dd1",
"class":"cell txt l",
"children":[
"Before transplantation: complete series if not already immune"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e3e13",
"class":"cell txt l",
"children":[
"Per recommendations for nontransplant patients"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9327c0",
"class":"cell txt l",
"children":[
"Recombinant zoster vaccine "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"919c64",
"class":"cell txt l",
"children":[
"Two doses for those ≥19 years of age (2nd dose 1-2 months later)"
]
},
" ",
{
"type":"p",
"hlId":"94033c",
"class":"cell txt l",
"children":[
"Should be given before transplantation, if possible"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39d232",
"class":"cell txt l",
"children":[
"Autologous stem cell transplantation: same as solid organ transplantation"
]
},
" ",
{
"type":"p",
"hlId":"dbaa52",
"class":"cell txt l",
"children":[
"Allogeneic stem cell transplantation: no recommendation"
]
},
" ",
{
"type":"p",
"hlId":"36656c",
"class":"cell txt l",
"children":[
"Should be given before transplantation if possible"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bbf892",
"class":"cell txt l",
"children":[
"Varicella"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f61c5",
"class":"cell txt l",
"children":[
">4 weeks before transplantation if not immune"
]
},
" ",
{
"type":"p",
"hlId":"f8e707",
"class":"cell txt l",
"children":[
"Contraindicated after transplantation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f61c5",
"class":"cell txt l",
"children":[
">4 weeks before transplantation if not immune"
]
},
" ",
{
"type":"p",
"hlId":"63ce1e",
"class":"cell txt l",
"children":[
"24 months after transplantation: two doses if seronegative and only if no GVHD or immunosuppression"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"71d07c",
"class":"cell txt l",
"children":[
"Human papillomavirus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"283a96",
"class":"cell txt l",
"children":[
"Before transplantation: per recommendations for nontransplant patients"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e3e13",
"class":"cell txt l",
"children":[
"Per recommendations for nontransplant patients"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"GVHD = graft-versus-host disease; HSCT = hematopoietic stem cell transplantation; MMR = measles, mumps, and rubella vaccine; PCV13 = 13-valent pneumococcal conjugate vaccine; PCV15 = 15-valent pneumococcal conjugate vaccine; PCV20 = 20-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine; Tdap = tetanus, diphtheria, and acellular pertussis vaccine."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"See ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s1_3",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
" for more information on vaccination recommendations and schedules."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"For multiple-dose immunizations, the time period between doses is generally 1-2 months."
]
]
}
}
}